Wells Fargo & Company Cuts MannKind (NASDAQ:MNKD) Price Target to $7.00

MannKind (NASDAQ:MNKD) had its target price trimmed by Wells Fargo & Company from $8.00 to $7.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the stock. Leerink Partners started coverage on shares of MannKind in a research report on Thursday, November 13th. They set an “outperform” rating and a $7.00 target price on the stock. Truist Financial set a $9.00 price objective on MannKind in a research note on Monday, November 24th. Weiss Ratings reissued a “hold (c)” rating on shares of MannKind in a report on Thursday, January 22nd. Zacks Research lowered MannKind from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of MannKind in a research report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.21.

MannKind Trading Up 1.2%

Shares of NASDAQ:MNKD opened at $3.28 on Friday. The business’s 50 day moving average is $5.55 and its 200-day moving average is $5.37. The firm has a market capitalization of $1.01 billion, a PE ratio of 164.08 and a beta of 0.84. MannKind has a 1-year low of $2.93 and a 1-year high of $6.51.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). MannKind had a negative return on equity of 11.12% and a net margin of 1.68%.The business had revenue of $111.96 million for the quarter, compared to analyst estimates of $99.85 million. During the same quarter in the prior year, the firm earned $0.03 EPS. The firm’s quarterly revenue was up 45.8% on a year-over-year basis. On average, sell-side analysts predict that MannKind will post 0.1 EPS for the current year.

Insider Buying and Selling at MannKind

In other MannKind news, insider Stuart A. Tross sold 47,006 shares of MannKind stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total value of $297,547.98. Following the completion of the transaction, the insider owned 985,007 shares in the company, valued at approximately $6,235,094.31. The trade was a 4.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Castagna sold 107,920 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $5.57, for a total value of $601,114.40. Following the sale, the chief executive officer owned 2,504,792 shares in the company, valued at $13,951,691.44. The trade was a 4.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 262,846 shares of company stock valued at $1,546,840. Corporate insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On MannKind

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd lifted its position in shares of MannKind by 108.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 2,927 shares in the last quarter. Quaker Wealth Management LLC raised its position in MannKind by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 7,000 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 14,000 shares during the last quarter. International Assets Investment Management LLC acquired a new position in MannKind during the 4th quarter worth $45,000. Huntington National Bank lifted its holdings in MannKind by 420.0% during the 4th quarter. Huntington National Bank now owns 10,400 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 8,400 shares in the last quarter. Finally, Burkett Financial Services LLC bought a new position in MannKind in the 4th quarter valued at $59,000. Institutional investors and hedge funds own 49.55% of the company’s stock.

Key MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.